Generic TENIPOSIDE INN equivalents, pharmaceutical patent and freedom to operate

Sponsor	Phase
Huashan Hospital	PHASE2
Shanghai Pulmonary Hospital, Shanghai, China	PHASE2
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD	PHASE2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Speclt Pharma	VUMON	teniposide	INJECTABLE;INJECTION	020119-001	Jul 14, 1992		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 4, 2026

Teniposide is a mature topoisomerase II inhibitor with a narrow oncology market, limited commercial visibility, and no credible path to blockbuster revenue. The drug was approved in the United States as Vumon for refractory childhood acute lymphoblastic leukemia, but its commercial position has weakened because of generic competition, low treatment volume, hospital procurement pressure, and substitution by etoposide-based and newer leukemia regimens. Public sources do not provide reliable standalone teniposide revenue figures. Its current financial value is better assessed through supply continuity, institutional purchasing, manufacturing economics, and residual clinical utility than through branded product sales.

What is teniposide and how is it used clinically?

Teniposide is a semisynthetic epipodophyllotoxin that inhibits topoisomerase II and causes DNA strand breaks. It is structurally related to etoposide but has a different side chain and greater lipophilicity.

The U.S. Food and Drug Administration approved teniposide injection in 1992 for use with other chemotherapeutic agents in the induction of remission in children with refractory acute lymphoblastic leukemia. The approved indication covers patients who have not responded adequately to prior therapy. The label does not position teniposide as a broad first-line leukemia treatment or as a general solid-tumor therapy [1].

Attribute	Teniposide
Active ingredient	Teniposide
Original brand	Vumon
Therapeutic class	Topoisomerase II inhibitor; epipodophyllotoxin
Primary FDA indication	Refractory childhood acute lymphoblastic leukemia
Dosage form	Intravenous injection
Typical institutional setting	Hospital oncology and pediatric oncology
Main pharmacologic comparator	Etoposide
Commercial model	Specialty injectable, institutionally purchased
Current market profile	Mature, low-volume, price-sensitive

The product is administered intravenously and requires handling by oncology centers. Important risks include myelosuppression, anaphylactoid reactions, mucositis, gastrointestinal toxicity, and secondary malignancies. These safety and administration requirements increase total treatment cost and limit use outside specialized centers [1].

When did teniposide lose market exclusivity?

Teniposide’s core composition-of-matter protection expired long before the current market period. The drug was commercially established decades ago, and any original U.S. patent term would have ended no later than the standard 20-year term measured from the relevant nonprovisional filing date, subject to historical patent-term rules and regulatory adjustments.

The commercial consequences are clear:

No meaningful new-molecule exclusivity remains.
The key competitive issue is generic manufacturing and supply reliability.
Any remaining intellectual-property value would relate to a specific formulation, manufacturing process, label, or delivery method rather than the basic teniposide molecule.
A Paragraph IV challenge is unlikely to be the primary market event for a product with such an old active ingredient and a narrow injectable market.

What is the Orange Book status of teniposide?

Teniposide has historically been associated with the Vumon NDA and later generic injectable products. The relevant Orange Book question is whether an active product listing and patent certifications remain attached to a currently marketed NDA or ANDA. For a mature injectable with no known current composition-of-matter barrier, the commercial constraint is more likely product availability than patent protection.

No current revenue thesis should assume that an Orange Book patent will delay generic competition. Any transaction or launch assessment should treat teniposide as effectively off-patent unless a live listing is confirmed in the current FDA Orange Book and the relevant product’s approval records.

How large is the teniposide market?

The teniposide market is small relative to major oncology drugs. Public market reports often combine teniposide with etoposide, podophyllotoxin derivatives, or broader cytotoxic oncology segments. Those reports generally do not isolate audited teniposide sales.

The market has four structural limitations:

The FDA-approved indication is narrow.
Treatment is concentrated in specialized pediatric and hospital settings.
Generic products compete largely on price and supply.
Clinicians have access to alternative regimens and the closely related etoposide.

Teniposide may retain demand in selected refractory leukemia protocols and in countries where historical treatment pathways continue to use the drug. That demand is unlikely to support large-scale commercial investment without a supply shortage, regulatory differentiation, or a new clinical use.

What is the financial trajectory for teniposide?

The financial trajectory is best characterized as long-term decline followed by a low, stable, and volatile specialty-generic phase.

Period	Commercial trajectory	Main drivers
1980s-1990s	Branded oncology growth	Introduction of Vumon and use in refractory leukemia
2000s	Maturity and erosion	Generic competition and broader treatment alternatives
2010s	Declining branded relevance	Hospital price pressure and limited label expansion
2020s	Niche injectable market	Supply continuity, shortages, procurement concentration, and low volumes

There is no dependable public basis for assigning a current annual revenue figure to teniposide alone. The product is not comparable with high-revenue oncology medicines such as pembrolizumab, daratumumab, or CAR-T therapies. Its financial profile is closer to a low-volume hospital injectable with episodic demand.

Revenue drivers

Teniposide revenue depends on:

Number of patients receiving refractory leukemia treatment
Use in institutional protocols
Number of approved suppliers
Contract pricing with hospitals and group purchasing organizations
Manufacturing yields and sterile-fill capacity
Raw-material availability
Product shortages affecting competing cytotoxic agents
Geographic differences in treatment standards

Revenue constraints

The largest constraints are clinical substitution and scale. Etoposide is more familiar, more broadly used, and available in multiple formulations. A manufacturer cannot rely on broad oncology demand to compensate for teniposide’s narrow label.

Margins may also be pressured by the economics of sterile injectable manufacturing. A low-volume product still requires validated aseptic production, quality testing, pharmacovigilance, regulatory maintenance, and controlled distribution. Those fixed costs can make the product unattractive even when the molecule itself is inexpensive.

How does teniposide compare with etoposide?

Etoposide is the stronger commercial product. It has wider clinical use, broader geographic availability, more established treatment protocols, and multiple dosage forms, including oral and intravenous products. Teniposide remains differentiated pharmacologically but lacks a comparable market footprint.

Factor	Teniposide	Etoposide
Clinical use	Narrower, concentrated in refractory pediatric leukemia and selected protocols	Broad use across hematologic and solid tumors
Formulations	Primarily intravenous	Intravenous and oral formulations in several markets
Generic depth	Limited in many markets	Broader supplier base
Prescriber familiarity	Lower	High
Commercial scale	Small	Substantially larger
Substitution risk	High	Lower because of broader protocol integration
Supply economics	Vulnerable to low-volume sterile manufacturing	Better supported by larger demand
Strategic attractiveness	Niche product or portfolio add-on	Established generic oncology platform

Teniposide’s differentiation from etoposide may support clinical use in selected patients, but it does not create a strong pricing advantage. In a hospital purchasing environment, the decision is usually driven by protocol, availability, safety experience, and price rather than molecular differentiation alone.

What formulations are protected by teniposide patents?

No commercially significant formulation exclusivity is apparent from the drug’s age and current market position. The principal marketed form is an intravenous solution. Potential technical issues include solubility, excipient compatibility, container interaction, stability, and sterile manufacturing, but these are manufacturing barriers rather than evidence of durable market exclusivity.

The product’s formulation profile creates operational risk:

Cytotoxic handling requires specialized facilities.
Intravenous products face sterility and particulate-matter controls.
Low annual volume can reduce manufacturing efficiency.
Stability and packaging requirements can limit contract-manufacturing options.
A shortage at one supplier can cause disproportionate market disruption.

A competitor could still obtain approval through an abbreviated pathway if it satisfies applicable quality, bioequivalence, labeling, and manufacturing requirements. Formulation complexity may slow entry, but it does not restore the commercial protection associated with a new chemical entity.

Are there Paragraph IV challenges to teniposide?

Paragraph IV litigation is not the central competitive risk for teniposide. The molecule is old, the market is narrow, and the primary commercial question is whether suppliers will enter or remain in the market rather than whether a major brand franchise can defend a high-value patent estate.

For a current generic applicant, relevant regulatory strategies would more likely involve:

Filing an ANDA against an eligible reference product
Demonstrating injectable-product equivalence
Addressing inactive ingredients and labeling
Managing manufacturing-site readiness
Assessing whether listed patents remain relevant
Establishing reliable commercial supply before launch

The absence of major public Paragraph IV activity should not be interpreted as evidence of a strong patent estate. It is more consistent with limited market value and limited incentive to litigate.

What is the FDA regulatory status of teniposide?

Teniposide has an established FDA regulatory history as an injectable oncology product. Its approval is tied to a narrow pediatric leukemia indication. The label carries serious warnings concerning bone marrow suppression, hypersensitivity reactions, and secondary malignancy risk [1].

The regulatory profile creates both barriers and limits:

The drug has an established clinical and regulatory pathway.
The indication is narrow, reducing market expansion potential.
Any new formulation or supplier must meet stringent sterile injectable standards.
Label expansion would require clinical evidence in a market where treatment alternatives already exist.
Manufacturing or quality failures could materially affect availability.

Teniposide is not a biologic and therefore does not face biosimilar competition. The relevant competition is conventional generic competition under the ANDA framework.

Which companies are challenging teniposide’s market position?

The main competitive pressure comes from manufacturers of generic teniposide and from suppliers of alternative chemotherapy agents. The most important clinical competitor is etoposide, which is produced by multiple generic and specialty pharmaceutical companies.

Competition is fragmented and often regional. Depending on the jurisdiction and period, teniposide supply may involve:

The original Vumon commercial franchise
Generic injectable manufacturers
Hospital and specialty distributors
Contract manufacturers supplying oncology injectables
Companies selling etoposide and other topoisomerase inhibitors

Publicly available information does not support a reliable ranking of current teniposide manufacturers by revenue or market share. Market concentration may change quickly when a supplier exits or experiences a manufacturing disruption.

What patent litigation affects teniposide?

No major current U.S. patent litigation appears to define the teniposide market. The drug’s economic exposure is more sensitive to product discontinuations, FDA manufacturing actions, shortages, and procurement changes than to ongoing branded patent litigation.

The most relevant legal risks are therefore operational:

Product liability claims associated with cytotoxic chemotherapy
Manufacturing-quality enforcement
Labeling disputes
Contract disputes with hospitals or distributors
Regulatory actions involving sterile production
Patent disputes over a new formulation or manufacturing process

A company evaluating acquisition or licensing should not assign material value to the historic Vumon brand without confirming current commercial rights, active registrations, supply contracts, and manufacturing ownership.

What generic entry risks exist for teniposide?

Generic entry risk is high, but the number of actual entrants may remain low because the market is economically unattractive. This distinction matters. A product can have weak patent protection and still have limited generic competition when demand is small and manufacturing costs are high.

The likely launch scenarios are:

Scenario	Market effect
One reliable generic supplier	Stable supply with moderate price pressure
Multiple generic suppliers	Lower prices and weaker margins
Supplier exit	Shortage risk and temporary pricing power
New formulation entrant	Possible differentiation, but limited market expansion
Clinical substitution	Permanent volume erosion

Generic entry is most likely to reduce the price of existing volume rather than expand the patient population. A new entrant would need either a lower-cost manufacturing model, a reliable shortage-replacement strategy, or a broader international distribution platform.

What geographic markets remain commercially relevant?

The United States remains important because of its regulatory standards and hospital oncology infrastructure, but the product’s volume is limited. European and other international markets may retain use through national protocols, hospital procurement, or historical availability.

Geographic value depends on:

Local treatment guidelines
National reimbursement
Registration status
Local generic competition
Import requirements
Availability of etoposide
Pediatric oncology center concentration

A global teniposide strategy would require country-by-country regulatory and supply analysis. U.S. approval does not ensure broad international market access, and an international registration may have little value without dependable local distribution.

How strong is the teniposide patent estate?

The patent estate is weak from a commercial exclusivity perspective. The active ingredient is old, the principal indication has been known for decades, and the market does not show the characteristics of a protected specialty product.

Patent category	Expected current strength
Composition of matter	Effectively expired
Original use patent	Historically expired or commercially immaterial
Formulation patent	Potentially relevant only if a specific live patent exists
Manufacturing patent	May protect process economics, not the molecule
Method-of-use patent	Limited value without a new, clinically adopted indication
Orange Book strategy	Low apparent importance
Trade secrets	Potentially relevant to yield, stability, or sterile processing

The strongest defensible asset would likely be manufacturing know-how or a differentiated dosage form, not the legacy drug patent. Any valuation should assign little or no value to historic composition-of-matter protection.

What licensing deals could support teniposide commercialization?

A licensing transaction would make economic sense only under narrow conditions. Possible transaction structures include:

Regional commercialization rights
Supply and distribution agreements
Acquisition of an approved injectable product
Contract manufacturing arrangements
Portfolio licensing with other hospital oncology drugs
Shortage-resilience agreements with institutional buyers

A standalone teniposide license would likely have limited upfront value. Its attractiveness would increase if bundled with etoposide, cytarabine, methotrexate, or other pediatric oncology injectables. Portfolio density can spread regulatory, sales, and manufacturing costs across several products.

Publicly disclosed licensing activity specifically centered on teniposide is limited. The absence of visible deal flow is consistent with a mature, low-revenue product rather than with a contested strategic asset.

What is the outlook for teniposide generic launch and investment value?

The base case is a small, stable, and increasingly procurement-driven market. Volume may persist because some oncology protocols and clinicians retain experience with the drug, but long-term growth is unlikely.

A commercially rational investment case would require at least one of the following:

A documented supply shortage
A defensible low-cost manufacturing process
Existing sterile injectable capacity
A multi-product hospital portfolio
Regulatory approvals in markets with persistent demand
A clinical niche where etoposide is unsuitable
An established oncology distribution network

Without those advantages, the product offers limited upside and high execution sensitivity. Revenue forecasting should use scenario analysis rather than a single market-growth assumption.

Key Takeaways

Teniposide is a mature, narrow-use oncology injectable with limited standalone revenue potential.
The FDA indication is refractory childhood acute lymphoblastic leukemia, not broad frontline cancer treatment.
Core patent exclusivity has expired; no meaningful composition-of-matter barrier remains.
Orange Book and Paragraph IV issues are secondary to manufacturing, supply, and procurement risks.
Etoposide is the principal commercial and clinical comparator and has a substantially stronger market position.
Teniposide is exposed to clinical substitution, low-volume sterile manufacturing costs, and hospital price pressure.
The drug is not subject to biosimilar competition because it is a conventional small-molecule medicine.
Publicly disclosed drug-level revenue and market-share data are not reliable enough to support a precise financial forecast.
The strongest commercial opportunity is a portfolio or supply-continuity strategy, not a standalone branded launch.
The base case is low, volatile revenue with occasional upside during supply shortages.

FAQs

Is teniposide still commercially available?

Availability depends on jurisdiction, supplier status, and hospital distribution. Products with small oncology markets can remain approved while experiencing intermittent supply constraints or limited commercial distribution.

Is teniposide more effective than etoposide?

Teniposide and etoposide are related topoisomerase II inhibitors, but one cannot be considered broadly superior across cancers. Choice depends on disease, treatment protocol, prior therapy, toxicity, and institutional practice.

Can a company obtain FDA approval for a generic teniposide injection?

Yes, subject to the applicable abbreviated approval pathway, product-quality requirements, injectable-product standards, labeling requirements, and reference-product considerations.

Does teniposide have biosimilar competition?

No. Teniposide is a small-molecule drug, so competitors are regulated as generic products rather than biosimilars.

Is teniposide an attractive pharmaceutical acquisition target?

As a standalone asset, generally no. Its value is more plausible within a broader hospital-oncology portfolio that can absorb manufacturing, regulatory, distribution, and pharmacovigilance costs.

References

U.S. Food and Drug Administration. (1992). Vumon (teniposide injection) prescribing information. FDA.
National Cancer Institute. (n.d.). Teniposide. National Cancer Institute Drug Dictionary.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
National Library of Medicine. (n.d.). Teniposide injection. DailyMed.
World Health Organization. (2023). WHO model list of essential medicines: 23rd list. World Health Organization.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	14
Drug Prices:	Drug price trends for TENIPOSIDE
What excipients (inactive ingredients) are in TENIPOSIDE?	TENIPOSIDE excipients list
DailyMed Link:	TENIPOSIDE at DailyMed

TENIPOSIDE - Generic Drug Details

What are the generic sources for teniposide and what is the scope of patent protection?

Summary for TENIPOSIDE

Recent Clinical Trials for TENIPOSIDE

Medical Subject Heading (MeSH) Categories for TENIPOSIDE

Anatomical Therapeutic Chemical (ATC) Classes for TENIPOSIDE

US Patents and Regulatory Information for TENIPOSIDE

Teniposide Market Dynamics and Financial Trajectory: Revenue Outlook, Competition, Regulation, and Patent Risk